Therapixel Case Study: AI MammoScreen 3D Detects Subtle Lesions

Ferrum Health partners with best-in-class AI providers offering solutions designed to reduce radiology workload and improve patient care.Therapixel Case Study: AI Detects Subtle LesionsIntroductionExcept for skin cancers, breast cancer is the most common cancer in women. When detected early, the 5-year survival rate is 99%. In a clinical study performed by Therapixel, cancer was detected utilizing MammoScreen® 3D one year earlier than by an unassisted radiologist reading.Clinical StudyArchitectural distortion in the upper outer left breast was detected in 2016 by the original reader. A prior exam dated 2015 was included in a clinical review in which MammoScreen highlighted the cancer with a score of 5. Thirteen radiologists recalled this case utilizing MammoScreen, while only 9 radiologists recalled it when unassisted. Additionally, utilizing MammoScreen reduced the reading time for this case by 21% on average.

ConclusionThe AI-guided detection support of MammoScreen empowers radiologists in their detection of subtle lesions improving the diagnosis time of cancer in patients.Interested in deploying MammoScreen at your health facility?Contact the Ferrum Health team to learn more.